ReachMD

Which breast cancer findings from ASCO 2026 are most relevant to your practice?

ASCO 2026 featured important research that may influence care across a range of patient populations. In this video brief, Dr. Aditya Bardia highlights notable studies, discusses their clinical implications, and explores how emerging data may inform treatment decision-making and patient care.

Explore the clinical implications of the latest breast cancer research: https://ow.ly/qkC550ZejxP

Could emerging therapies have a role in maladaptive FSGS?

This discussion explores how therapies under review may extend beyond primary FSGS to what is now referred to as maladaptive FSGS. Early observations suggest potential applicability, highlighting an area of interest for future clinical use.

Explore how these insights may shape patient care: https://ow.ly/vs0p50YFHB0

Future Directions in FSGS Care Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that...

Join a leading Spanish expert for a live, interactive webinar series exploring how perioperative immunotherapy may shape evolving treatment strategies in resectable, locally advanced HNSCC. He'll cover patient selection, sequencing approaches, multidisciplinary care integration, and more. Register now: https://ow.ly/sxiG50Zb7Xk

How should adjuvant therapy be optimized for patients with HER2-positive early breast cancer who remain at high risk after neoadjuvant treatment? The phase 3 DESTINY-Breast05 trial compared T-DXd with T-DM1 and helped inform updated NCCN guidance.

Explore the data in this video brief from ASCO 2026: https://ow.ly/SqlJ50ZabNV